Clough Capital Partners L P Mirati Therapeutics, Inc. Transaction History

Clough Capital Partners L P

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$39.16 - $88.71 $2.07 Million - $4.69 Million	-52,902 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $3.61 Million - $7.18 Million	-47,553 Reduced 47.34%	52,902 $4.35 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $6.75 Million - $9.72 Million	51,100 Added 103.54%	100,455 $14.7 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $6.52 Million - $8.76 Million	-49,360 Reduced 50.0%	49,355 $8.73 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $12 Million - $15 Million	83,410 Added 544.99%	98,715 $15.9 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $63,567 - $88,644	-400 Reduced 2.55%	15,305 $2.62 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $8.5 Million - $12.6 Million	-52,465 Reduced 76.96%	15,705 $3.45 Million
Q3 2020 Nov 17, 2020	SELL	$113.26 - $167.27 $7 Million - $10.3 Million	-61,790 Reduced 47.55%	68,170 $11.3 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $1.56 Million - $2.61 Million	21,660 Added 20.0%	129,960 $14.8 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $7.56 Million - $12.6 Million	108,300 New	108,300 $8.33 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

Stay updated on Clough Capital Partners L P with notifications on news.